RSV is an important disease in infants and children less than 5 years old, as well as in older persons over 65 years old. According to the CDC, each year in the United States, RSV leads to approximately 58,000-80,000 hospitalizations of children younger than 5 years old and 100-300 deaths in children younger than 5 years old. It also leads to 60,000-160,000 hospitalizations among adults 65 and older, and 6,000-10,000 deaths of adults 65 and older.
Ribavirin is the only currently approved drug for RSV infection, that can be used only as a last resort because of its extensive toxicity that limits its effectiveness.
This company’s study has achieved an extremely significant result in the fight against RSV! RSV is an important disease in infants and children less than 5 years old, as well as in older persons over 65 years old. According to the CDC, each year in the United States, RSV leads to approximately 58,000-80,000 hospitalizations of children younger than 5 years old and 100-300 deaths in children younger than 5 years old. It also leads to 60,000-160,000 hospitalizations among adults 65 and older, and 6,000-10,000 deaths of adults 65 and older.
Ribavirin is the only currently approved drug for RSV infection, that can be used only as a last resort because of its extensive toxicity that limits its effectiveness.
This company’s study has achieved an extremely significant result in the fight against RSV! Learn how this company could see tremendous growth ahead with a novel broad-spectrum antiviral that has activity against RSV!
--
